Limits...
Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening.

Kitagawa Y, Mizokami A, Namiki M - Prostate Int (2013)

Bottom Line: The rate of localized disease was significantly higher in the PSA testing group than in the other groups.The probability of nonrecurrence of the patients in the PSA testing group was significantly higher than in the other groups.These patients have better prognosis than those with symptoms.

View Article: PubMed Central - PubMed

Affiliation: Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.

ABSTRACT

Purpose: Due to the low rate of screening for prostate cancer in Japan, the incidence rates of cancer are high. We have established a prostate-specific antigen (PSA)-based screening system for prostate cancer in our region. We analyzed recent trends of clinical symptoms and prognosis of prostate cancer patients aged 55 to 69 years old in our institution.

Methods: Between 2000 and 2007, 162 cases of prostate cancer in patients aged 55 to 69 years old were newly diagnosed. The study population was divided into 119 cases with high PSA without symptoms, 36 cases with urological symptoms, and 7 cases with systemic symptoms. We analyzed the clinical courses of the patients in each group.

Results: The rate of localized disease was significantly higher in the PSA testing group than in the other groups. The median serum PSA levels were 1,600 ng/mL in the systemic symptom group, 13.3 ng/mL in the urological symptom group, and 7.1 ng/mL in the PSA testing group. The probability of nonrecurrence of the patients in the PSA testing group was significantly higher than in the other groups.

Conclusions: The rate of prostate cancer patients diagnosed by PSA testing was relatively high in our institution. These patients have better prognosis than those with symptoms.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier plots of cancer-specific survival rates of prostate cancer patients in prostate-specific antigen (PSA) testing, urological symptom, and systemic symptom groups. *P<0.01.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3814114&req=5

f1-pi_1-2-65-03: Kaplan-Meier plots of cancer-specific survival rates of prostate cancer patients in prostate-specific antigen (PSA) testing, urological symptom, and systemic symptom groups. *P<0.01.

Mentions: Serum PSA levels could be obtained for all patients at a mean postdiagnosis follow-up of 37.1 months. Five patients (3.1%) died of prostate cancer, and clinical and/or biochemical recurrence occurred in 19 patients (11.7%). Cancer-specific survival rates for each group are shown in Fig. 1. The probabilities of survival at 5 years were 98.2% and 96.3% for the PSA testing and urological symptom groups, respectively. In contrast, the corresponding percentage for the patients in the systemic symptom group was 40.0%; this difference was statistically significant.


Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening.

Kitagawa Y, Mizokami A, Namiki M - Prostate Int (2013)

Kaplan-Meier plots of cancer-specific survival rates of prostate cancer patients in prostate-specific antigen (PSA) testing, urological symptom, and systemic symptom groups. *P<0.01.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3814114&req=5

f1-pi_1-2-65-03: Kaplan-Meier plots of cancer-specific survival rates of prostate cancer patients in prostate-specific antigen (PSA) testing, urological symptom, and systemic symptom groups. *P<0.01.
Mentions: Serum PSA levels could be obtained for all patients at a mean postdiagnosis follow-up of 37.1 months. Five patients (3.1%) died of prostate cancer, and clinical and/or biochemical recurrence occurred in 19 patients (11.7%). Cancer-specific survival rates for each group are shown in Fig. 1. The probabilities of survival at 5 years were 98.2% and 96.3% for the PSA testing and urological symptom groups, respectively. In contrast, the corresponding percentage for the patients in the systemic symptom group was 40.0%; this difference was statistically significant.

Bottom Line: The rate of localized disease was significantly higher in the PSA testing group than in the other groups.The probability of nonrecurrence of the patients in the PSA testing group was significantly higher than in the other groups.These patients have better prognosis than those with symptoms.

View Article: PubMed Central - PubMed

Affiliation: Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.

ABSTRACT

Purpose: Due to the low rate of screening for prostate cancer in Japan, the incidence rates of cancer are high. We have established a prostate-specific antigen (PSA)-based screening system for prostate cancer in our region. We analyzed recent trends of clinical symptoms and prognosis of prostate cancer patients aged 55 to 69 years old in our institution.

Methods: Between 2000 and 2007, 162 cases of prostate cancer in patients aged 55 to 69 years old were newly diagnosed. The study population was divided into 119 cases with high PSA without symptoms, 36 cases with urological symptoms, and 7 cases with systemic symptoms. We analyzed the clinical courses of the patients in each group.

Results: The rate of localized disease was significantly higher in the PSA testing group than in the other groups. The median serum PSA levels were 1,600 ng/mL in the systemic symptom group, 13.3 ng/mL in the urological symptom group, and 7.1 ng/mL in the PSA testing group. The probability of nonrecurrence of the patients in the PSA testing group was significantly higher than in the other groups.

Conclusions: The rate of prostate cancer patients diagnosed by PSA testing was relatively high in our institution. These patients have better prognosis than those with symptoms.

No MeSH data available.


Related in: MedlinePlus